No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer
- 01.01.2015
- original article
Erschienen in:
- Verfasst von
- Dominik Riss, MD
- Johannes Pammer, MD
- Matthaeus C. Grasl, MD, MME
- Alexandra Kaider, MSc
- Sven Schneider, MD
- Boban M. Erovic, MD, PD
- Erschienen in
- Wiener klinische Wochenschrift | Ausgabe 1-2/2015
Summary
Purpose
To investigate the role of desmocollin 3 expression in radiation sensitivity and survival in squamous cell carcinoma of the head and neck.
Methods
Tissue samples of 40 patients undergoing primary radiotherapy were stained for desmocollin 3, a transmembrane desmosomal protein. The protein expression was determined by immunohistochemistry. A retrospective chart review was performed to assess overall survival, radiation sensitivity, and disease-free interval.
Results
18 of 40 patients showed desmocollin 3 immunoreactivity. 78 % (14/18) showed radiation sensitivity in the desmocollin 3 positive group, whereas 59 % (13/22) underwent remission in the desmocollin 3 negative group (p = 0.2). The median overall and disease-free survival time was 21 and 26 months, respectively. Univariate and multivariable Cox regression models revealed no statistically significant hazard ratios.
Conclusion
In this cohort of squamous cell carcinoma of the head and neck, we found no evidence for a predictive potential of desmocollin 3.
Anzeige
- Titel
- No evidence for desmocollin 3 to serve as a prognostic marker in primary radiotherapy of head and neck cancer
- Verfasst von
-
Dominik Riss, MD
Johannes Pammer, MD
Matthaeus C. Grasl, MD, MME
Alexandra Kaider, MSc
Sven Schneider, MD
Boban M. Erovic, MD, PD
- Publikationsdatum
- 01.01.2015
- Verlag
- Springer Vienna
- Erschienen in
-
Wiener klinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671 - DOI
- https://doi.org/10.1007/s00508-014-0618-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.